Market revenue in 2023 | USD 122.4 million |
Market revenue in 2030 | USD 331.3 million |
Growth rate | 15.3% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase IV |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.26% in 2023. Horizon Databook has segmented the South Korea cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Korea is rapidly becoming recognized as a leader in clinical research, standing as a Top 10 location globally in terms of the number of studies conducted yearly. In December 2018, the Korean government designated 184 medical institutions as qualified clinical trial sites.
South Korea has conducted the highest number of industry-sponsored Cell and Gene Therapy Clinical Trials than any other Asian countries between 2011 & 2018. South Korea saw 2,210 such trials, compared to 1,627 in Australia and 1,585 in Japan over the same period. The country has one of the most efficient clinical trial approvals of 30 working days.
It has a research intensive environment, rapid expenditure on R&D, and advanced IT infrastructure with a highly educated & motivated resources, sites in Korean have established track records in quality as well as efficiency in cell and gene therapy clinical trials.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Korea cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account